
NVX Valuation
NOVONIX Ltd
NVX Relative Valuation
NVX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVX is overvalued; if below, it's undervalued.
Historical Valuation
NOVONIX Ltd (NVX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.20 is considered Undervalued compared with the five-year average of -33.97. The fair price of NOVONIX Ltd (NVX) is between 6.80 to 23.24 according to relative valuation methord. Compared to the current price of 1.18 USD , NOVONIX Ltd is Undervalued By 82.64%.
Relative Value
Fair Zone
6.80-23.24
Current Price:1.18
82.64%
Undervalued
0.00
PE
1Y
3Y
5Y
Trailing
Forward
-9.87
EV/EBITDA
NOVONIX Ltd. (NVX) has a current EV/EBITDA of -9.87. The 5-year average EV/EBITDA is -34.27. The thresholds are as follows: Strongly Undervalued below -154.12, Undervalued between -154.12 and -94.20, Fairly Valued between 25.65 and -94.20, Overvalued between 25.65 and 85.57, and Strongly Overvalued above 85.57. The current Forward EV/EBITDA of -9.87 falls within the Historic Trend Line -Fairly Valued range.
-7.51
EV/EBIT
NOVONIX Ltd. (NVX) has a current EV/EBIT of -7.51. The 5-year average EV/EBIT is -11.04. The thresholds are as follows: Strongly Undervalued below -104.66, Undervalued between -104.66 and -57.85, Fairly Valued between 35.77 and -57.85, Overvalued between 35.77 and 82.57, and Strongly Overvalued above 82.57. The current Forward EV/EBIT of -7.51 falls within the Historic Trend Line -Fairly Valued range.
1.20
PS
NOVONIX Ltd. (NVX) has a current PS of 1.20. The 5-year average PS is 67.81. The thresholds are as follows: Strongly Undervalued below -97.21, Undervalued between -97.21 and -14.70, Fairly Valued between 150.32 and -14.70, Overvalued between 150.32 and 232.83, and Strongly Overvalued above 232.83. The current Forward PS of 1.20 falls within the Historic Trend Line -Fairly Valued range.
2.05
P/OCF
NOVONIX Ltd. (NVX) has a current P/OCF of 2.05. The 5-year average P/OCF is -64.39. The thresholds are as follows: Strongly Undervalued below -276.59, Undervalued between -276.59 and -170.49, Fairly Valued between 41.71 and -170.49, Overvalued between 41.71 and 147.81, and Strongly Overvalued above 147.81. The current Forward P/OCF of 2.05 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
NOVONIX Ltd. (NVX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
NOVONIX Ltd (NVX) has a current Price-to-Book (P/B) ratio of 5.31. Compared to its 3-year average P/B ratio of 2.85 , the current P/B ratio is approximately 86.53% higher. Relative to its 5-year average P/B ratio of 4.80, the current P/B ratio is about 10.63% higher. NOVONIX Ltd (NVX) has a Forward Free Cash Flow (FCF) yield of approximately -36.37%. Compared to its 3-year average FCF yield of -28.51%, the current FCF yield is approximately 27.55% lower. Relative to its 5-year average FCF yield of -19.26% , the current FCF yield is about 88.80% lower.
5.31
P/B
Median3y
2.85
Median5y
4.80
-36.37
FCF Yield
Median3y
-28.51
Median5y
-19.26
Competitors Valuation Multiple
The average P/S ratio for NVX's competitors is 14.49, providing a benchmark for relative valuation. NOVONIX Ltd Corp (NVX) exhibits a P/S ratio of 1.20, which is -91.72% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NVX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NVX in the past 1 year is driven by Unknown.
People Also Watch

HDSN
Hudson Technologies Inc
6.850
USD
+2.24%

FOA
Finance of America Companies Inc
22.320
USD
+1.59%

DBI
Designer Brands Inc
4.080
USD
+2.26%

ATGL
Alpha Technology Group Ltd
15.420
USD
-2.41%

ACRS
Aclaris Therapeutics Inc
2.320
USD
+2.20%

DRTS
Alpha Tau Medical Ltd
3.860
USD
+1.47%

VYGR
Voyager Therapeutics Inc
4.230
USD
+0.24%

EM
Smart Share Global Ltd
1.360
USD
-0.73%

PAL
Proficient Auto Logistics Inc
6.600
USD
-5.31%
FAQ
Is NOVONIX Ltd (NVX) currently overvalued or undervalued?
NOVONIX Ltd (NVX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.20 is considered Undervalued compared with the five-year average of -33.97. The fair price of NOVONIX Ltd (NVX) is between 6.80 to 23.24 according to relative valuation methord. Compared to the current price of 1.18 USD , NOVONIX Ltd is Undervalued By 82.64% .








